Strategic partnerships Iconovo collaborates with large pharma players and has recent partnership with Lonza to develop spray-dried intranasal biologic formulations, signaling interest and capability to engage in co-development with contract manufacturers and biotech groups.

Inhalation leadership Awards and recognition as Best Inhalation Therapy Company in 2024 position Iconovo as a credible partner for inhalation-focused programs, enhancing credibility when approaching potential customers and collaborators.

Nasal delivery focus Recent updates show active development of nasal ICOone inhalers and improved nasal devices, suggesting opportunities to target ENT, vaccine delivery, and intranasal biologics programs seeking robust dry powder inhaler solutions.

Early-stage milestone Revenue remains low and funding modest, but ongoing Q1-2024 reporting and grant activity indicate a company in growth and proof-of-concept phase, ideal for early-stage partnerships, licensing deals, and pilot projects.

Global market focus Grants and collaborations aimed at markets like South Korea, plus a strategy centered on international pharmaceutical collaborations, opening sales opportunities across regional CROs, CMOs, and pharma companies pursuing global inhalation solutions.